Spots Global Cancer Trial Database for jdq443
Every month we try and update this database with for jdq443 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | NCT05714891 | NSCLC | JDQ443 | 18 Years - | Canadian Cancer Trials Group | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | NCT05445843 | Locally Advance... | JDQ443 | 18 Years - | Novartis | |
| JDQ443 for KRAS G12C NSCLC Brain Metastases | NCT05999357 | Non Small Cell ... Brain Metastase... KRAS G12C | JDQ443 | 18 Years - | Maastricht University Medical Center | |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | NCT05132075 | Non-Small Cell ... | JDQ443 docetaxel | 18 Years - | Novartis | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | NCT05329623 | Small Cell Lung... | JDQ443 | 18 Years - 75 Years | Novartis | |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. | NCT05445843 | Locally Advance... | JDQ443 | 18 Years - | Novartis | |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | NCT05132075 | Non-Small Cell ... | JDQ443 docetaxel | 18 Years - | Novartis | |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT04699188 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Colo... Cancer of Lung Cancer of the L... Lung Cancer Neoplasms, Lung Neoplasms, Pulm... Pulmonary Cance... Pulmonary Neopl... | JDQ443 TNO155 tislelizumab | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
